A5101547041- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Nutrition and Health in Aging
- Gastric Cancer Management and Outcomes
- Viral-associated cancers and disorders
- Colorectal and Anal Carcinomas
- Sarcoma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Pituitary Gland Disorders and Treatments
- Frailty in Older Adults
- Thyroid Cancer Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Cytomegalovirus and herpesvirus research
- Cancer, Stress, Anesthesia, and Immune Response
- BRCA gene mutations in cancer
- Cancer, Hypoxia, and Metabolism
- Inflammatory Biomarkers in Disease Prognosis
- Esophageal and GI Pathology
- Hepatitis C virus research
- Neuroendocrine Tumor Research Advances
- Intraperitoneal and Appendiceal Malignancies
The Cancer Institute Hospital
2020-2025
Japanese Foundation For Cancer Research
2020-2025
University of Tokyo Hospital
2024
Tokyo Medical and Dental University
2024
Memorial Sloan Kettering Cancer Center
2024
Niigata University
2021
Niigata Prefectural Ojiya Nishi High School
2021
Tosei General Hospital
2017-2020
Toyama University Hospital
2017-2020
Nagoya University
1995-2017
Some targeted therapies alter muscle mass due to interference with pathways of metabolism. The effects mammalian target ra pamycin (mTOR) inhibitors on have yet be fully elucidated. In the present study, computerized tomography (CT) scans patients receiving mTOR for at least 6 months taken baseline and post‑therapy were retrospectively retrieved, body composition analyses performed using software, sliceOmatic version 5.0 (TomoVision, Inc., Magog, QC, Canada). difference in parameters was...
Neuroendocrine carcinoma (NEC) of the head and neck is a rare type malignancy, accounting for only 0.3% all cancers, its clinicopathological genomic features have not been fully characterized. We conducted retrospective analysis 27 patients with poorly differentiated NEC seen at our institution over period 15 years. Patient characteristics, adopted therapies, clinical outcomes were reviewed based on medical records. Pathological targeted sequencing 523 cancer-related genes performed using...
Abstract Background Beneficial effects of napping on cognition have been suggested in cross-sectional studies. This study aimed to clarify longitudinal associations between cognitive decline and sleep characteristics, particularly daytime napping, over a 5-year period older adults. Methods Study participants were 389 community-dwelling individuals aged ≥65 years living Ojiya City, Niigata, Japan. Baseline follow-up examinations conducted 2011–2013 2016–2018, respectively. Trained nurses...
Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer (ATC). However, tumor markers ATC treated lenvatinib lacking. The aim this study was to explore whether neutrophil-to-lymphocyte ratio (NLR) can be a marker lenvatinib. Patients and Methods: We retrospectively analyzed prognostic significance NLR in 13 Results: disease control rate better lower (<8; 89%) than higher (≥8; 25%) (p=0.05). Median progression-free survival overall were longer (4.0...
Abstract Background Comprehensive genomic profiling (CGP) provides new opportunities for patients with advanced cancer to receive genome-matched therapies, but the availability rate of these remains low. We reviewed our CGP cases and suggested possible strategies improve current status from a clinical perspective. Methods Druggable alterations barriers accessing therapies were investigated in 653 30 various types cancers who underwent CGP. Results While as whole was 9.5%, useful some types....
Neuroendocrine carcinoma (NEC) is a rare and aggressive malignancy derived from multiple body parts, with the urogenital organs being second-largest extrapulmonary sites. The detailed mechanism of bladder NEC pathogenesis remains unknown. We reviewed data 23 patients diagnosed (bladder prostate) conducted targeted sequencing 523 cancer-related genes, focusing on NEC. While 14 cases featured pure histology, remaining nine included histology mixed other tumors, such as urothelial (UC) or...
11144 Background: Cancer types in Adolescents and Young Adults (AYA) vary by age. Since many AYA cancers are classified as rare, patients continue to face limited therapeutic options. This study evaluates the utility of comprehensive genomic profiling (CGP) genome-matched therapies for cancer patients, considering age-specific variations using a nationwide database. Methods: We analyzed data from 2,325 (aged 15–39) who underwent CGP between 2019 2023. The landscape treatment status were...
Abstract Cancer genomic profile (CGP) testing, which is covered by the national health insurance system in Japan, has been introduced as a routine clinical practice. However, effects of CGP testing on prognoses remain unclear. Drug accessibility rates and after were retrospectively investigated 713 patients who underwent examined our molecular tumor board between November 2019 October 2022,. Overall survival (OS) was using log‐rank test Kaplan–Meier method. The median age (326 males 387...
We investigated the interobserver variation in prostate target volume and trend toward use of diagnostic computed tomography (CT) or magnetic resonance (MR) images for treatment planning. Twenty-five radiation oncologists were asked to draw external contour on CT (0.3 cm spacing) a patient with localized cancer. They also answered questionnaire regarding MR contouring. Of 25 physicians, 28% rarely never referred images. In contrast, physicians tended refer more frequently. Approximately 50%...
Patients with muscle-invasive bladder cancer (MIBC) often undergo various preoperative treatments to improve survival; however, their efficacy and safety remain unclear.The anti-tumour effects adverse events were evaluated in 163 MIBC patients who received systemic chemotherapy (SC, n = 34), intra-arterial (IAC, 50), or combined IAC radiotherapy (IAC + R, 79).Pathological complete responses observed 17.6%, 22.0%, 43.0% of the SC, IAC, R groups, respectively, respective 5-year overall...
Lenvatinib is a standard therapy for radioiodine-refractory differentiated thyroid cancer (RR-DTC). However, because of the high incidence adverse events resulting from this treatment, it not easy to maintain dose intensity lenvatinib, especially in Japanese patients. Although prognostic impact lenvatinib interruption has been reported, target optimize survival benefits remains unknown. We therefore propose during first 8 weeks treatment. retrospectively analyzed 42 RR-DTC patients who were...
There have been few reports on the evaluation of cancer cachexia based skeletal muscle mass index (SMI) in patients with head and neck cancer.One hundred ninety-two were enrolled. In definitive adjuvant chemoradiotherapy settings, clinical outcomes compared between non-cachexia patients.Forty diagnosed (20.8%). setting, overall survival (OS) was significantly shorter group (3-year OS: 50.0% vs 88.5%; p < 0.01), multivariate analysis identified UICC stage IV, baseline albumin <4 as poor...
Comprehensive cancer genomic profile (CGP) tests are being implemented under Japanese universal health insurance system. However, the clinical usefulness of CGP test for breast patients has not been evaluated. Of 310 who underwent testing at our institution between November 2019 and April 2021, 35 with metastatic whose treatment strategy was discussed by molecular tumor board within study period were investigated after exclusion 2 cases that could be analyzed. The turn-around time, drug...
Abstract The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fusions. Recently, immune checkpoint inhibitors have shown efficacy patient mutation burden-high (TMB-H) been established as a third agent, making it necessary to develop the guideline...
Abstract Flow cytometric analysis of CD4 + and CD8 T cells specific to human cytomegalovirus (CMV) was undertaken in seven patients with congenital CMV infection, six healthy infants who had acquired CMV‐seropositive adults. Intracellular cytokine assays showed that 0.03–2.23% the adults produced interferon‐γ (IFN‐γ) response antigens. In contrast, such were almost undetectable infection younger than 2 years age. Tetrameric major histocompatibility complex/peptide complex demonstrated...
The aim of this study was to evaluate the efficacy and safety CapeOX plus bevacizumab with a planned oxaliplatin stop-and-go strategy in Japanese patients metastatic colorectal cancer (mCRC).Patients untreated mCRC were treated 4 cycles therapy, followed by capecitabine maintenance therapy. Reintroduction scheduled after 8 therapy or upon tumor progression. primary endpoint progression-free survival (PFS), secondary end points included overall (OS), objective response rate each treatment,...
Pazopanib with trabectedin and eribulin is widely used to treat soft-tissue sarcoma (STS). We have shown that baseline neutrophil-to-lymphocyte ratio (NLR) may predict the efficacy patient prognosis of eribulin. Changes in NLR, but not can trabectedin. However, prognostic factors pazopanib for STS been identified. present a retrospective analysis 141 patients treated recurrent or metastatic non-round cell STS. Univariate multivariate analyses were performed determine predictive durable...
Abstract A fixed‐dose formula that combines Ombitasvir (OBV), Paritaprevir (PTV) and Ritonavir (RTV) has been launched into the field of anti‐HCV therapy in Japan for patients infected with HCV genotypes 1 2 2015. However, little is yet known as to efficacy safety this novel on maintenance haemodialysis (HD). The present report describes a preliminary experience 10 (five males five females) who underwent HD. All them had genotype 1b, without having resistance‐associated variants at Y93 or...